John M. Burke, MD

Oncology trials often celebrate treatments improving progression-free survival, yet toxicity-related censoring can bias results. Emphasizing overall survival and quality of life offers clearer insights into true clinical benefit.

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most obesity-related cancers, offering promise in decreasing the overall cancer burden in the US.

As gene editing technology continues to advance, it could fundamentally change the landscape of cancer treatment.

The 2024 ASCO Annual Meeting was invigorating and inspired a renewed commitment to advancing cancer treatment.

A cyberattack on Change Healthcare disrupted patient scheduling, billing, and potentially exposed patient data. It caused financial strain on medical practices and took weeks to recover from.

John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for the treatment of early-stage and advanced classical Hodgkin lymphoma.

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.

Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.

If the title is correct, an article in the November 10 issue of the Journal of Clinical Oncology shows that many randomized trials in oncology are improperly designed and many drugs used in oncology have been approved based on the wrong end point.

According to John M. Burke, MD, it is hard to imagine that results presented at ESMO in the urothelial cancer space will not lead to the complete replacement of conventional chemotherapy as the standard first-line treatment.

John M. Burke, MD, discusses the 2 phase 3 trials presented at the 2023 ASH Annual Meeting that have potential to be practice changing for patients with multiple myeloma and chronic lymphocytic leukemia.

In this article, John M. Burke, MD, discusses the high prices of prescription drugs and the new law that allows the government to negotiate drug prices with manufacturers.

John M. Burke, MD, discusses how Bruton tyrosine kinase inhibitors have demonstrated unexpected promise in treating follicular lymphoma, challenging previous assumptions in the field of oncology.

During the plenary session of the 2023 American Society of Clinical Oncology Annual Meeting, we learned that BV-AVD’s reign at the top may be short lived.

John M. Burke, MD, turns to ChatGPT to uncover what artificial intelligence may do for hematologists/oncologists.

John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.

According to John M. Burke, MD, significant attention has been paid in recent years to the problem of physician burnout and as oncologists continue to care for patients, it important to also care for themselves.

Additional data emerged demonstrating the value of blinatumomab not only in patients with relapsed acute lymphoblastic leukemia but also in those with detectable minimal residual disease.

After a meeting like the 2022 ASCO Annual Meeting, one cannot help but be reinvigorated to continue advancing cancer care and feel optimistic about the future of oncology, says John M. Burke, MD.

In this month's 10-year anniversary issue of Targeted Therapies in Oncology™, we feature an article on the evolution of immunotherapy approaches in oncology over the past decade.

Improving our diagnostic and prognostic testing capabilities is one of the most important and exciting ways to improve how we care for patients with cancer, according to John M. Burke, MD.

Amid the surge of the omicron variant, the FDA issued an emergency use authorization for the orally administered antiviral combination, which can reduce the rate hospitalization or death by 87% compared with no treatment.

Clinical trial findings presented during the ASH annual meeting have the potential to change the management of diffuse large B-cell lymphoma, according to John M. Burke, MD.

The future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.

Suggestions to hematologist-oncologists when talking to patients with relapsed/refractory diffuse large B-cell lymphoma about the potential benefits of CAR T-cell therapy and toxicities.

Recommendations to increase the uptake of CAR T-cell therapies into clinical practice when managing patients with relapsed/refractory diffuse large B-cell lymphoma.

Variables that are likely to impact the use of loncastuximab vs a combination approach with tafasitamab and lenalidomide to treat relapsed/refractory diffuse large B-cell lymphoma.

An overview of the LOTIS-1 clinical trial and the rationale for the accelerated approval of loncastuximab for relapsed/refractory diffuse large B-cell lymphoma.

Recommendations for managing patients with diffuse large B-cell lymphoma on tafasitamab.